Oxidation of debrisoquine by marmoset CYP2D enzymes, CYP2D19 and CYP2D30

被引：0
|
作者：
Narimatsu, S
Kuramoto, S
Hichiya, H
Yamamoto, S
Asaoka, K
Miyata, A
Kiryu, K
Ueda, N
Naito, S
Ellis, SW
机构：
[1] Okayama Univ, Fac Pharmaceut Sci, Lab Hlth Chem, Okayama, Japan
[2] Okayama Univ, Fac Pharmaceut Sci, Lab Biomol Sci, Okayama, Japan
[3] Kyoto Univ, Primate Res Inst, Dept Mol Physiol, Aichi, Japan
[4] Kagoshima Univ, Sch Med, Dept Pharmacol, Kagoshima 890, Japan
[5] Otsuka Pharmaceut Factory Inc, Res & Dept, Tokushima, Japan
[6] Univ Sheffield, Sect Mol Pharmacol & Pharmacogenet, Sheffield, S Yorkshire, England
来源：
DRUG METABOLISM REVIEWS | 2003年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
384
引用
收藏
页码：192 / 192
页数：1
相关论文
共 50 条
  • [31] Gene expression and cellular localization of isoenzymes of the CYP2A, CYP2C, CYP2D and CYP2E subfamilies in the intestines and liver in horse
    Tyden, E.
    Bjornstrom, H.
    Tjalve, H.
    Larsson, P.
    JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2009, 32 : 86 - 87
  • [32] Linkage disequilibrium characterization of CYP2C and CYP2D genomic regions in European populations
    不详
    PHARMACOGENOMICS, 2013, 14 (05) : 460 - 461
  • [33] Lack of relationships between the debrisoquine (CYP2D6) and mephenytion (CYP2C19) oxidation polymorphisms and susceptibility to breast cancer
    Jennings, M
    Sweetland, H
    Smith, CAD
    Wolf, CR
    Lennard, MS
    Tucker, GT
    Woods, HF
    Rogers, K
    BREAST, 1996, 5 (04): : 254 - 258
  • [34] Characterization of the oxidation reactions catalyzed by CYP2D enzyme in rat renal microsomes
    Masubuchi, Y
    Yamamoto, K
    Suzuki, T
    Horie, T
    Narimatsu, S
    LIFE SCIENCES, 1996, 58 (26) : 2431 - 2437
  • [35] Debrisoquine hydroxylase (CYP2D6) and prostate cancer
    Febbo, PG
    Kantoff, PW
    Giovannucci, E
    Brown, M
    Chang, G
    Hennekens, CH
    Stampfer, M
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1998, 7 (12) : 1075 - 1078
  • [36] Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations
    S. Wanwimolruk
    S. Bhawan
    P. F. Coville
    S. C. W. Chalcroft
    European Journal of Clinical Pharmacology, 1998, 54 : 431 - 435
  • [37] Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations
    Wanwimolruk, S
    Bhawan, S
    Coville, PF
    Chalcroft, SCW
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (05) : 431 - 435
  • [38] DOES CIGARETTE SMOKING, WHEN COMBINED WITH NAFLD, ALTER THE EXPRESSION OF CYP2D AND CYP2C?
    Pilote, S.
    Thibauilt, C.
    Jubinville, E.
    Routhier, J.
    Morissette, M. C.
    Drolet, B.
    Simard, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S87 - S88
  • [39] Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17
    Shen, Hongwu
    He, Minxia M.
    Liu, Houfu
    Wrighton, Steven A.
    Wang, Li
    Guo, Bin
    Li, Chuan
    DRUG METABOLISM AND DISPOSITION, 2007, 35 (08) : 1292 - 1300
  • [40] Changes in maternal liver Cyp2c and Cyp2d expression and activity during rat pregnancy
    Dickmann, Leslie J.
    Tay, Suzanne
    Senn, Tauri D.
    Zhang, Huixia
    Visone, Anthony
    Unadkat, Jashuant D.
    Hebert, Mary F.
    Isoherranen, Nina
    BIOCHEMICAL PHARMACOLOGY, 2008, 75 (08) : 1677 - 1687
12345